Citizens initiated coverage of Stereotaxis (STXS) with an Outperform rating and $4 price target Stereotaxis develops robotic platforms for use in endovascular surgeries, the analyst tells investors in a research note. The firm views the company as a “unique micro-cap MedTech name worth owning” due to its key product developments set to be tailwinds for system adoption and improved procedural utilization through 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STXS: